In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

1. The FDA has approved a supplemental Biologics License Application for brentuximab vedotin (Adcetris, Seagen Inc.), in combination with lenalidomide and rituximab, for adults with relapsed or ...

The company already has two other cancer drugs approved – Adcetris (brentuximab vedotin) for certain forms of lymphoma and Padcev (enfortumab vedotin) for advanced bladder cancer. The FDA had ...

In January and February of this year, the US Food and Drug Administration granted approvals for Adcetris (brentuximab vedotin), Lumakras (sotorasib), Grafapex (treosulfan), Enhertu (fam ...

FDA Approves Brentuximab Vedotin Triplet in R/R Large B-cell Lymphoma The FDA also approved the combination of brentuximab vedotin (Adcetris), lenalidomide (Revlimid) and rituximab (Rituxan) for adult ...

Seagen has a long history in ADC development, claiming FDA approval for Adcetris (brentuximab vedotin) as a treatment for classical Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL ...

For more info on trial data, access the full article here. The combination of brentuximab vedotin (Adcetris), lenalidomide (Revlimid), and rituximab (Rituxan) has received FDA approval for the ...

On February 12, 2025, PFE’s supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product was approved by the U.S. FDA ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...